Skip to main content
ABL Bio Inc. logo

ABL Bio Inc. — Investor Relations & Filings

Ticker · 298380 ISIN · KR7298380007 LEI · 9884007BRC71Y64NK235 KO Professional, scientific and technical activities
Open in API
Filings indexed 368 across all filing types
Latest filing 2023-04-07 Major Shareholding Noti…
Country KR South Korea
Listing KO 298380

About ABL Bio Inc.

https://www.ablbio.com

ABL Bio Inc. is a clinical-stage biotechnology company specializing in the development of bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. The company leverages several proprietary platforms. For central nervous system disorders, its 'Grabody-B' technology is a blood-brain barrier (BBB) penetrating shuttle designed to enhance drug delivery to the brain. In immuno-oncology, ABL Bio develops 4-1BB based bispecific antibodies aimed at minimizing toxicity and overcoming resistance to existing immunotherapies. The company is also advancing a pipeline of antibody-drug conjugates (ADCs) with an improved therapeutic index for conditions such as rare blood cancers. ABL Bio actively progresses its therapeutic candidates through clinical development.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and their special related parties, including information on stock collateral loans and market sales. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2023-04-07 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results from a General Meeting of Shareholders (AGM). It details the voting outcomes for various agenda items, including financial statement approval, director appointments, and auditor committee appointments. This fits the definition of a Declaration of Voting Results (DVA) as it provides the official outcome of shareholder votes.
2023-03-30 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options). It details the issuance of stock options to employees, including the number of shares, exercise price, and vesting conditions, submitted to the Financial Services Commission/Korea Exchange. This type of disclosure regarding equity-based compensation and capital structure changes falls under the category of share issues or capital changes.
2023-03-30 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment of outside directors (사외이사의 선임). It details the names, backgrounds, and terms of the newly appointed directors following an Annual General Meeting. This falls under the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors.
2023-03-30 Korean
투자판단관련주요경영사항(이중항체 면역항암제 ABL503의 국내 제1상 임상시험계획 (IND) 승인)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) system, specifically a 'Major Management Matter' disclosure regarding the approval of a Phase 1 clinical trial (IND) for a drug candidate (ABL503). Since this is a formal regulatory announcement of a material business event (clinical trial approval) and does not fit into specific categories like financial reports, dividends, or M&A, it is classified as a Regulatory Filing (RNS).
2023-03-29 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by ABL Bio. It details the date, location, and agenda items for the upcoming Annual General Meeting, including the approval of financial statements, election of directors, and appointment of audit committee members. This type of document is sent to shareholders to provide information and request votes for the meeting, which aligns perfectly with the definition of a Proxy Solicitation & Information Statement.
2023-03-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.